GSK:LON
GSK plc
GBX 1,761.00
arrow_upward
+0.11%(+2.00) 1D
Oct 6, 4:39:33 PM GMT+1 · GBX
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
GBX 1,769.50
High
GBX 1,786.50
Low
GBX 1,740.50
Mkt. cap
95.42B
Avg. vol.
5.40M
Volume
5.02M
Dividend
3.86%
Quarterly dividend
GBX 17.00
Ex-dividend date
Aug 13, 2026
P/E ratio
14.92
52-wk high
GBX 2,282.00
52-wk low
GBX 1,592.00
EPS
GBX 1.18
Shares outstanding
4.05B
No. of employees
67K
Open
GBX 1,769.50
High
GBX 1,786.50
Low
GBX 1,740.50
Mkt. cap
95.42B
Avg. vol.
5.40M
Volume
5.02M
Dividend
3.86%
Quarterly dividend
GBX 17.00
Ex-dividend date
Aug 13, 2026
P/E ratio
14.92
52-wk high
GBX 2,282.00
52-wk low
GBX 1,592.00
EPS
GBX 1.18
Shares outstanding
4.05B
No. of employees
67K
News stories
From web sources and news partners
Kalkine Media
·
6 hours ago
GSK Announces Admission of 19,352 Shares Under Share Save Plan to London Stock Exchange
Stock Titan
·
9 hours ago
19,352 GSK (GSK) shares join London trading under its Share Save Plan 2022.
TipRanks
·
9 hours ago
GSK Adds Shares Under Employee Plan to London Listing
Kalkine Media
·
12 hours ago
Why Is GSK (LSE:GSK) Stock Back In Focus This Week After The Nuvalent Agreement?
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66.8K
FoundedDec 27, 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com